Sign in

ANIX on Nasdaq

Anixa Biosciences Inc

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines.1 It is headquartered in San Jose, California.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Nexentis Technologies Inc., Clene Inc. or NOMAD POWER SOLUTIONS, INC., or pick any stock.

  • TickerANIX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Jose, California1
  • Incorporated inDE2
  • Business address3150 Almaden Expressway, Suite 250, San Jose, Ca 951182
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Biosciences, Inc. is a biotechnology company developing therapies and vaccines that are focused on critical unmet needs in oncology.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-6586.2%Operating margin4
-5978.1%Net margin4
0.0%Revenue growth, 20245
-62.8%Return on equity4

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Research and development100¢$6.4M

Out of $210.0K in revenue.54 The company lost money this year.

Financial statements

Revenue675$210.0K in 2024−16% since 2019
0$200.0K$400.0K$600.0K2019: $250.0K$250.0K20192021: $512.0K$512.0K2021+105%2023: $210.0K$210.0K2023−59%2024: $210.0K$210.0K2024+0%
Operating income687954-$13.8M in 2024+16% since 2019
-$15.0M-$10.0M-$5.0M02019: -$11.9M-$11.9M20192020: -$10.0M-$10.0M2020−16%2021: -$13.1M-$13.1M2021+32%2022: -$13.9M-$13.9M2022+6%2023: -$11.0M-$11.0M2023−21%2024: -$13.8M-$13.8M2024+26%
Net income687954-$12.6M in 2024+8% since 2019
-$15.0M-$10.0M-$5.0M02019: -$11.6M-$11.6M20192020: -$10.0M-$10.0M2020−14%2021: -$13.0M-$13.0M2021+29%2022: -$13.6M-$13.6M2022+5%2023: -$9.8M-$9.8M2023−28%2024: -$12.6M-$12.6M2024+28%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-10-312024-10-31
Research and development expenses (including non-cash stock-based compensation expenses of $1,560 and $1,859, respectively)$5.1M$6.4M
General and administrative expenses (including non-cash stock-based compensation expenses of $2,250 and $2,923, respectively)$6.6M$7.4M
Total operating costs and expenses$11.7M$13.8M
Loss from operations-$11.7M-$13.8M
Interest income$673.0K$1.1M
Net loss-$11.0M-$12.7M
Less: Net loss attributable to noncontrolling interest-$101.0K-$144.0K
Net loss attributable to common shareholders-$10.9M-$12.6M
Basic-$0.34-$0.39
Diluted-$0.34-$0.39
Basic32.5K shares31.9K shares
Diluted32.5K shares31.9K shares

Compare Anixa Biosciences Inc with another company

Corporate structure

Anixa Biosciences Inc sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Anixa Biosciences Inc

  • Michael Catelani Filed SCHEDULE 13D/A on Anixa Biosciences Inc, latest Jan 6, 2026 (2 filings since May 3, 2024)
  • Amit Kumar Filed SCHEDULE 13D/A on Anixa Biosciences Inc, latest Jun 6, 2025 (3 filings since Jan 16, 2024)
  • Anixa Biosciences Inc San Jose, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Anixa Biosciences Inc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Operating-lease assets (leased space)$193.0K4 Oct 31, 2025$229.0K4 Oct 31, 2024−15.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.2M4 Oct 31, 2025$1.3M4 Oct 31, 2024−2.1%
Marketable securities, current$13.9M4 Oct 31, 2025$18.7M4 Oct 31, 2024−25.3%

Properties, in its own words

We lease approximately 2,000 square feet of office space at 3150 Almaden Expressway, San Jose, California 95118 (our principal executive offices) from an unrelated party pursuant to a lease that expires September 30, 2027, with an option to extend the lease an additional two years. Our base rent is approximately $5,000 per month and the lease provides for annual increases of approximately 3% and an escalation clause for increases in certain operating costs.

Item 2 of the 10-K filed Jan 12, 2026.3

Leadership

Who has led Anixa Biosciences Inc, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Denis A. Krusos2006–2012
  2. Lewis H. Titterton Jr.2012

President

  1. Frank J. Disanto2006–2007
  2. Michael Catelani2022–now

Chief financial officer

  1. Henry P. Herms2006–2016
  2. Michael Catelani2016–now

Chief operating officer

  1. Tisha Stender2014
  2. Michael Catelani2017–now
2010201520202025
Board members and other officers (13)

Former names

  • ITUS CorpSep 2, 2014 to Sep 27, 20182
  • COPYTELE INCSep 6, 1995 to Aug 27, 20142

Timeline

  1. Mar 11, 20268-K Shareholder vote; Regulation FD disclosure31
  2. Feb 9, 20268-K Regulation FD disclosure32
  3. Dec 12, 20258-K Regulation FD disclosure33
  4. Mar 21, 20258-K Shareholder vote; Regulation FD disclosure34
  5. Nov 8, 20248-K Regulation FD disclosure35
  6. May 8, 20248-K Entered a material agreement; Regulation FD disclosure36
  7. Mar 22, 20248-K Shareholder vote; Regulation FD disclosure37
  8. Dec 7, 20238-K Regulation FD disclosure38
  9. Apr 17, 20238-K Regulation FD disclosure39
  10. Mar 10, 20238-K Shareholder vote; Regulation FD disclosure40
  11. Dec 8, 20228-K Regulation FD disclosure41
  12. Sep 29, 20228-K Regulation FD disclosure42
  13. Sep 14, 2012New chief executive Lewis H. Titterton Jr. becomes CEO13
  14. Jun 5, 2006New chief executive Denis A. Krusos becomes CEO14

Filings

159 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 18 major events, 97 insider forms, 5 large holders, 19 other. The latest 20:

  1. Sep 30, 20264 EDGAR
  2. Sep 28, 20264 EDGAR
  3. Sep 28, 20264 EDGAR
  4. Sep 25, 20264 EDGAR
  5. Sep 14, 20264 EDGAR
  6. Sep 14, 20264 EDGAR
  7. Sep 11, 20264 EDGAR
  8. Sep 9, 202610-Q EDGAR
  9. Aug 3, 20264 EDGAR
  10. Jul 29, 20264 EDGAR
  11. Jul 28, 20264 EDGAR
  12. Jul 27, 20264 EDGAR
  13. Jul 27, 20264 EDGAR
  14. Jul 21, 20264 EDGAR
  15. Jul 20, 20264 EDGAR
  16. Jul 16, 20264 EDGAR
  17. Jul 13, 20264 EDGAR
  18. Jun 17, 20264 EDGAR
  19. Jun 16, 20264 EDGAR
  20. Jun 10, 202610-Q EDGAR

The 159 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

59 open-market trades by officers, directors and large owners since October 2021: 58 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 30, 2026Catelani MichaelPresident, COO, & CFOBuy5,500$2.84$15.6KForm 4
Sep 24, 2026KUMAR AMITChief Executive OfficerBuy7,000$2.78$19.5KForm 4
Sep 24, 2026Baskies Arnold MDirectorBuy5,000$2.76$13.8KForm 4
Sep 23, 2026Titterton Lewis H jrDirectorBuy49,036$2.69$131.9KForm 4
Sep 10, 2026KUMAR AMITChief Executive OfficerBuy3,000$2.75$8.2KForm 4
Sep 10, 2026Titterton Lewis H jrDirectorBuy10,000$2.73$27.3KForm 4
Sep 10, 2026KUMAR AMITChief Executive OfficerBuy5,000$2.76$13.8KForm 4
Jul 31, 2026KUMAR AMITChief Executive OfficerBuy5,000$3.47$17.4KForm 4
Jul 27, 2026KUMAR AMITChief Executive OfficerBuy5,000$3.44$17.2KForm 4
Jul 27, 2026KUMAR AMITChief Executive OfficerBuy3,188$3.37$10.7KForm 4
Jul 24, 2026KUMAR AMITChief Executive OfficerBuy3,000$3.73$11.2KForm 4
Jul 20, 2026KUMAR AMITChief Executive OfficerBuy5,000$3.46$17.3KForm 4
Jul 20, 2026Titterton Lewis H jrDirectorBuy12,000$3.47$41.6KForm 4
Jul 15, 2026Titterton Lewis H jrDirectorBuy2,797$3.28$9.2KForm 4
Jul 10, 2026KUMAR AMITChief Executive OfficerBuy5,000$3.04$15.2KForm 4
Jun 16, 2026Titterton Lewis H jrDirectorBuy2,836$2.64$7.5KForm 4
Jun 12, 2026KUMAR AMITChief Executive OfficerBuy21,000$2.50$52.5KForm 4
Jan 28, 2026Baskies Arnold MDirectorBuy10,000$3.04$30.4KForm 4
Jul 31, 2025Titterton Lewis H jrDirectorBuy10,000$3.08$30.8KForm 4
Jul 30, 2025KUMAR AMITChief Executive OfficerBuy5,000$3.16$15.8KForm 4

All 59 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Michael CatelaniSCHEDULE 13D/A, 2 filings May 3, 2024 to Jan 6, 202643
  • Amit KumarSCHEDULE 13D/A, 3 filings Jan 16, 2024 to Jun 6, 202544

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Dr. Amit Kumar61$815.2K$2.5M45
2025Michael J. Catelani59$553.2K$1.3M45
2024Chairman of the Board and Chief Executive Officer$785.5K$3.5M45
2024PresidentChief Operating Officer and Chief Financial Officer$533.0K$1.8M45

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 61. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC1,329,852$3.7M0.0%+14,870
UBS Group AG585,430$1.6M0.0%+33,793
Laird Norton Wetherby Trust Company, LLC578,727$1.6M0.0%+12,400
D.a. Davidson & Co.539,272$1.5M0.0%No change
Geode Capital Management, LLC359,194$1.0M0.0%−5,537
Marshall Wace, Llp328,332$919.3K0.0%+155,153
BlackRock, Inc.199,755$559.3K0.0%+29,652
Vanguard Fiduciary Trust Co192,356$538.6K0.0%+1,282
State Street Corp159,040$445.3K0.0%No change
LPL Financial LLC111,535$312.3K0.0%+30,559
Northern Trust Corp69,235$193.9K0.0%+2,410
Renaissance Technologies LLC59,373$166.2K0.0%−1,800
CoreCap Advisors, LLC52,020$145.7K0.0%No change
Bank of New York Mellon Corp47,442$132.8K0.0%No change
Westside Investment Management, Inc.43,000$120.4K0.0%−4,000
HighTower Advisors, LLC41,150$115.2K0.0%−400
Kestra Advisory Services, LLC38,000$106.4K0.0%−13,000
Corient Private Wealth LP37,400$104.7K0.0%+17,400
Gemmer Asset Management LLC35,000$98.0K0.0%No change
Modern Wealth Management, LLC32,000$89.6K0.0%New
Citadel Advisors LLC31,887$89.3K0.0%New
Vontobel Holding Ltd.30,000$84.0K0.0%No change
CIBC Bancorp USA Inc.26,600$74.5K0.0%No change
Nations Financial Group Inc, /ia/ /adv22,500$63.0K0.0%No change
Keybank National Association/oh15,810$44.3K0.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Anixa Biosciences Inc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAnixa Biosciences Inc1
  • CIK0000715446
  • Employer ID (EIN)11-26226303
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsOctober 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address3150 Almaden Expressway, Suite 250, San Jose, CA 951181
  • Phone408-708-98081
  • Shares outstanding34,763,802 as of Sep 9, 202612
  • Public float$85.1M as of Apr 30, 20253
  • AuditorHASKELL & WHITE LLP, Irvine, California PCAOB ID 200; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceJun 9, 19951
  • Filings980 in all: 4 (433), 8-K (114), 10-Q (95), DEF 14A (31), 10-K (27), CORRESP (25), UPLOAD (25), S-8 (22)1
    All 49 form types

    SC 13D/A (21), 3 (19), EFFECT (13), 10-K/A (12), 5 (11), DEFA14A (11), SC 13D (9), 424B3 (8), S-3 (8), 424B5 (7), PRE 14A (7), 10-Q/A (6), CT ORDER (6), NT 10-K (6), S-3/A (6), D (5), 10-K405 (4), NT 10-Q (4), POS AM (4), SC 13G (4), 4/A (3), 424B2 (3), S-1 (3), S-8 POS (3), SC 13G/A (3), SCHEDULE 13D/A (3), 3/A (2), AW (2), FWP (2), S-1/A (2), 10-C (1), 10-K405/A (1), 144 (1), 8-A12B (1), ARS (1), CERTNAS (1), DEL AM (1), DFAN14A (1), PREC14A (1), PRER14A (1), RW (1)

  • Latest filingsAnnual report (10-K) Jan 12, 2026
    Quarterly report (10-Q) Sep 9, 2026
    Proxy statement (DEF 14A) Jan 28, 2026
    Latest 8-K (8-K) Mar 11, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.01 par valueANIXNASDAQ

From the cover page of the 10-K filed Jan 12, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Anixa Biosciences Inc names in Item 1A of its 10-K filed Jan 12, 2026: 40 risks under these headings, as written.3

  • Risks Related to Our Financial Condition and Operations
  • We have a history of losses and may incur additional losses in the future.
  • We will need additional funding in the future which may not be available on acceptable terms, or at all, and, if available, may result in dilution to our stockholders.
  • We may have difficulty in raising capital and may consume resources faster than expected.
  • Failure to effectively manage our potential growth could place strains on our managerial, operational and financial resources and could adversely affect our business and operating results.
  • We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.
  • Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
  • Risks Related to our Research & Development, Clinical and Commercialization Activities
  • Our therapeutic and vaccine programs are pre-revenue, and subject to the risks of an early-stage biotechnology company.
  • Our current business model relies on strategic collaborations with commercial partners to provide the resources and infrastructure to manufacture and ultimately market and/or sell our technologies. We may have difficulty in timing the establishment of these partnerships to achieve the greatest economic benefit for the Company, or in establishing these partnerships at all.
  • If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.
  • If we cannot license rights to use technologies on reasonable terms, we may not be able to commercialize new products in the future.
The other 30 risks
  • Biotechnology and pharmaceutical product development is a highly speculative undertaking and involves a substantial degree of uncertainty. We have never generated any revenue from biotechnology and pharmaceutical product sales and our biotechnology and pharmaceutical products may never be profitable.
  • Cancer vaccines are novel and present significant challenges.
  • CAR-T cell therapies are novel and present significant challenges.
  • While CAR-T technology has shown positive results in B cell cancers by others, its safety and efficacy has not been seen in solid tumors and we cannot guarantee our CAR-T technology will be safe or effective in ovarian or other cancers.
  • While pre-clinical testing and the limited human clinical testing of our product candidates has been positive, we may experience unfavorable results once we collect statistically significant data from human clinical trials.
  • We are dependent on third parties to conduct our pre-clinical studies and clinical trials.
  • If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
  • Any adverse developments that occur during any clinical trials conducted by academic investigators, our collaborators or other entities conducting clinical trials under independent IND applications may negatively affect the conduct of our clinical trials or our ability to obtain regulatory approvals or commercialize our product candidates.
  • Adverse side effects or other safety risks associated with our product candidates could cause us to suspend or discontinue clinical trials or delay or preclude approval.
  • Vaccine hesitancy, misinformation about vaccine safety, and evolving positions of public health authorities on vaccines could adversely affect the development and commercial success of our cancer vaccine product candidates.
  • Clinical trials are expensive, time consuming and difficult to design and implement.
  • We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.
  • Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.
  • We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.
  • The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.
  • Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers, third-party payors and others in the medical community.
  • Risks Related to Our Intellectual Property
  • If we are unable to obtain and maintain intellectual property protection, our competitive position will be harmed.
  • Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.
  • We rely on licenses from Wistar for our CAR-T technology and Cleveland Clinic for our cancer vaccine technologies, and if we lose any of these licenses we may be subjected to future litigation.
  • If our efforts to protect the proprietary nature of our technologies are not adequate, we may not be able to compete effectively in our market.
  • Obtaining and maintaining our patents depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent position could be reduced or eliminated for non-compliance with these requirements.
  • Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO.
  • We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.
  • Risks Related to Our Common Stock
  • The issuance or sale of shares in the future to raise money or for strategic purposes could reduce the market price of our common stock.
  • We may fail to meet market expectations because of fluctuations in quarterly operating results, which could cause the price of our common stock to decline.
  • Biotechnology company stock prices are especially volatile, and this volatility may depress the price of our common stock.
  • Our common stock is currently listed on NASDAQ Capital Market, however if our common stock is delisted for any reason, it will become subject to the SEC’s penny stock rules which may make our shares more difficult to sell.
  • We have issued a significant number of securities pursuant to our incentive plans and may continue to do so in the future. The vesting and, if applicable, exercise of these securities and the sale of the shares of common stock issuable thereunder may dilute stockholders’ percentage ownership interest and may also result in downward pressure on the price of our common stock.
  • We are a smaller reporting company and the reduced reporting requirements applicable to smaller reporting companies may make our common stock less attractive to investors.
  • We do not anticipate declaring any cash dividends on our common stock which may adversely impact the market price of our stock.

Legal proceedings

Other than lawsuits we bring to enforce our patent rights, we are not a party to any material pending legal proceedings, nor are we aware of any pending litigation or legal proceeding against us that would have a material adverse effect on our financial position or results of operations.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45